Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Ms Marie-Christine Alessi
Clinical guidelines have recommended that individuals with risk factors for coronary heart disease should take aspirin for primary and secondary prevention. However subgroups analyses did not demonstrate any significant effect on reducing vascular events in patients suffering diabetes. More recently, two large primary prospectively designed prevention trials confimed these findings (JPAD, JAMA 2008 and POPADAD , Brit Med J 2008). These data question the causes of the clinical and biological non responsivness to aspirin in diabetics. Several hypotheses were put forward by Professor Patrono (Roma, It) to explain aspirin resistance in diabetic patients : glycation of COX1, rendering COX1 more effective, increased COX2 expression bypassing COX 1 and lastly a faster recovery of COX 1 activity in diabetic patients, reducing aspirin efficiency. This last hypothesis was nicely documented. Some heterogeneity in COX1 recovery has been observed suggesting that enhanced platelet turnover in a fraction of type 2 diabetes may allow sufficient recovery of COX1 activity and may blunt the aspirin effect.
Similarly to aspirin resistance, clopidogrel non responsivness is more frequently observed in diabetics. To overcome this difficulty, DJ angiolillo (Jacksonville, US) nicely described recent data showing the advantages of increasing clopidogrel doses, the benefit of combining clopidogrel with cilostazol or picotamide and the promise of new antiplatelet drugs.
In association to strict metabolic control, it is probable that ongoing trials focusing on the use of antiplatelet agents in diabetics will help to explore alternative regimens of antiplatelet therapy and to identify patients that may benefit from tailored antiplatelet treatment.
The diabetic platelet - an unsolved problem